Industry market size, geographic breakdown, company revenue, and brand-level product sales
DataPorium delivers healthcare sector analytics across pharmaceuticals, biotech, and medical devices. Track company performance, compare players within a sub-sector, and study market-share dynamics to see who is gaining ground — turning raw industry data into clear competitive intelligence for investors and analysts.
Healthcare is a vast, fast-moving sector spanning drug makers, biotech innovators, medical-device manufacturers, insurers, and care providers. What sets it apart is how much value hinges on competitive position: a single approval, patent, or shift in market share can reshape an entire category. That is why healthcare analytics works best when it goes beyond price to capture who is winning and why. The same data is also available through the DataPorium financial data API.
Effective sector analysis starts by grouping companies into comparable segments — large-cap pharma, emerging biotech, devices, services — then comparing growth, profitability, and market share within each. Rising share often signals a stronger product pipeline or pricing power, while eroding share can foreshadow trouble. Because healthcare is defensive and demographic-driven, pairing competitive intelligence with economic indicators helps you separate durable leaders from short-term movers.
The Drug Approvals section lists every US approval of a new drug, a biologic, a generic drug and a new use, with novel drugs marked. The Clinical Trials section covers every registered clinical study with its phase, status, conditions, drugs, sponsor, dates and enrollment, and both are updated daily.
It covers pharmaceutical, biotech, and medical-device companies, along with sector trends and competitive intelligence such as market share and product positioning.
Track company performance, compare players within a sub-sector, and study market-share dynamics to understand who is gaining or losing ground across drugs, devices, and services.
Healthcare is a large, defensive sector driven by innovation, regulation, and demographics, which makes competitive intelligence especially valuable for spotting winners early.
The Drug Approvals section lists every US approval of a new drug, a biologic, a generic and a new use, and the Clinical Trials section covers every registered clinical study with its phase, status, conditions and sponsor. On the stock page, the Drug Pipeline tab shows the approvals and trials of one company.
45 novel drugs were approved in the United States in 2026 as of September 30, 2026, after 46 in 2025. A novel drug is the first approval of a new active ingredient.
AstraZeneca PLC (AZN) is the lead sponsor of 566 active clinical trials, 198 of them in phase 3. Drugs in its active phase 3 trials include ALXN2220, Saruparib, Enzalutamide, Darolutamide.
Novartis AG (NVS) is the lead sponsor of 369 active clinical trials, 91 of them in phase 3. Drugs in its active phase 3 trials include Abelacimab, zigakibart, atrasentan, Remibrutinib.
Pfizer Inc. (PFE) is the lead sponsor of 251 active clinical trials, 85 of them in phase 3. Drugs in its active phase 3 trials include Abrocitinib, PF-08634404, Pembrolizumab, Semaglutide.
Roche Holding AG (ROG.SW) is the lead sponsor of 247 active clinical trials, 90 of them in phase 3. Drugs in its active phase 3 trials include NXT007, Trontinemab, Afimkibart, Giredestrant.
Johnson & Johnson (JNJ) is the lead sponsor of 240 active clinical trials, 74 of them in phase 3. Drugs in its active phase 3 trials include Ramantamig, Daratumumab, Lenalidomide, Bortezomib.
AbbVie Inc. (ABBV) is the lead sponsor of 238 active clinical trials, 61 of them in phase 3. Drugs in its active phase 3 trials include Telisotuzumab Adizutecan, Docetaxel, Ramucirumab, Etentamig.
Bristol-Myers Squibb Company (BMY) is the lead sponsor of 234 active clinical trials, 66 of them in phase 3. Drugs in its active phase 3 trials include BMS-986353, Fludarabine, Cyclophosphamide, Tocilizumab.
Eli Lilly and Company (LLY) is the lead sponsor of 234 active clinical trials, 97 of them in phase 3. Drugs in its active phase 3 trials include Orforglipron, Tirzepatide, Dulaglutide, Brenipatide.
A health savings account used as a retirement account is deductible going in, untaxed while growing and tax free for medical costs: $8,750 a year for 25 years at 7% builds about $553,000.
The Social Security and Medicare Trustees 2026 reports project the retirement trust fund depleted in 2032 with 78% of benefits payable, and Medicare's hospital fund depleted in 2033 paying 89%.
Pharma stocks are the one S&P 500 group with falling earnings in Q2 2026, yet Lilly grew revenue 48% and Merck raised guidance; the sector trades at a trailing P/E of 22.1.